[250 Pages Report] The global sphingolipids market was valued at about US$ 564.0 Million in 2021, with the global market estimated to surge ahead at a CAGR of 5.1% to reach an estimated valuation of around US$ 991.8 Million by the end of 2032. Conventional lipid-based drug delivery systems (LBDDS) are driving the global sphingolipids market as of 2021, holding a 61.9% global market share.
Market Outlook:
| Data | Market Insight |
|---|---|
| Market Value 2021 | US$ 564.0 Million |
| Estimated market Value 2022 | US$ 601.3 Million |
| Estimated market Value 2032 | US$ 991.8 Million |
| CAGR of 2022 to 2032 | 5.1% |
| Market share of Top 5 countries | 66.3% |
| Key Market players | Merck KGaA, CordenPharma International, Lipoid GmbH, LARODAN AB, Croda International Plc., Biosynth, Santa Cruz Biotechnology, Inc., Creative Enzymes, CD Bioparticles, Cayman Chemical Company, and Others (Biosolve BV and others) |
Sphingolipids are a subclass of lipids with sphingoid bases as their backbone, a group of aliphatic amino alcohols that also includes sphingosine. Sphingolipids have many biological activities and are abundant in the central nervous system (CNS). They take part in tissue formation, cell identification, and adhesion, and function as toxin receptors. They are crucial for a number of biological functions, including differentiation, apoptosis, and signaling.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The sphingolipids market is expected to hold a market value of US$ 564.0 Million by 2032. Overall, sphingolipids market sales account for approximately 2.8% revenue share in the global pharmaceutical lipids market, which was valued at around US$ 4.4 Billion in 2021.
The global sphingolipids market recorded a CAGR of 4.7% in the historic years from 2012 to 2021.
Sphingolipids are thought of as essential excipients in the pharmaceutical as well as cosmetics industries for the production of numerous prescription drugs. They take on many different functions, including those of solubilizes, transfection agents, stabilisers, permeation enhancers, and others.
Throughout the anticipated years, the market is expected to be driven by the increasing use of semi-synthetic, synthetic, natural, or entirely man-made sphingolipids and monomers in the manufacturing of various pharmaceutical formulations.
In addition, an emerging factor driving the expansion of the worldwide sphingolipids market is enhanced drug delivery technology through prescription medications. The frequency of dispersion, level of emulsification, size of the particles, and other design elements will also contribute to the market's expansion sphingolipids market.
The manufacturing of liposomal drugs for the treatment of cancer, cardiovascular disorders, chronic illnesses, and excipients is being fuelled by the global need for pharmaceuticals. These drivers will cause the sphingolipids market to expand steadily over the forecast period.
Sphingolipids have been shown to be essential in preventing pulmonary leaks and lung injury during the past several years, and altering their routes may be a method for therapeutic interventions.
For instance, the WHO reports that dangerous and challenging-to-treat pneumonia is the most typical diagnosis among individuals with severe COVID-19 & cardiac illness. Acute respiratory distress syndrome (ARDS) is typically associated with patients who have an overactive inflammatory response.
In order to prevent the rapid clinical deterioration of individuals with COVID-19 and cardiovascular disorders, it may be necessary to take action on numerous different levels.
The aforementioned factors are expected to serve as probable market drivers for the global sphingolipids market and help the market to expand significantly in the forecast period.
Sales of pharmaceutical lipids are expected to be driven by rising demand for pharmaceutical sphingolipids, as a result of chronic diseases, the high prevalence of cancer, as well as a growing emphasis on physical well-being.
Sphingolipids appear to be strong contenders for use in the food, cosmetics, pharmaceutical, and healthcare industries. The potential of sphingolipid molecules will grow in the future as more and more new sources and structures are identified. The potential to use chemical techniques to change the structure of natural sphingolipids can also expand the range of applications for them.
Manufacturers can concentrate on creating products using natural sphingolipids, which can be extracted from biological samples and further modified chemically to produce sphingolipid compounds with novel features that are appealing to be used in cosmetic, pharmaceutical, and medical applications.
For instance, phenethyl isothiocyanate and 4-sphingosine can be coupled to have greater inhibitory activity against the proliferation of human leukaemia cells.
The abovementioned factors are capable of acting as lucrative opportunities for manufacturers operating in the sphingolipids market.
Principal Consultant
Some adverse reactions, including peripheral neuropathy brought on by paclitaxel, may be dose-limiting, further lowering the efficacy of paclitaxel chemotherapy. Radiation and chemotherapy treatments can have serious effects on young female patients' ability to conceive if their ovarian failure occurs prematurely.
Sphingolipids have been found to contribute to the side effects of cancer treatments in recent years. Sphingolipids have been demonstrated to be dysregulated in cancer and have a significant role in both cell proliferation and death.
There are more rules to control the quality and effectiveness of medications as a result of the global pharmaceutical industry's expansion. When it comes to following a nation's legal standards for the drug development process, regulatory authorities and organisations are crucial.
The standards for producing lipid-based excipients are not currently defined by any established rules. However, despite the fact that many manufacturing facilities do not follow IPEC criteria, most manufacturers generally accept them.
The above-mentioned factors can challenge the market expansion of the global sphingolipids market.
The USA held the greatest share in the regional sphingolipids market with about 94.5% share at the end of the year 2021. The biggest market for sphingolipids is the USA This is because there are numerous manufacturers in this industry and sphingolipids are in great demand across a variety of end-use sectors.
As of 2021, Germany is leading the European market withholding about 32.5% of the regional market share with a valuation of around US$ 49.7 Million. The market is primarily driven by the growing knowledge of the nutritional and functional value of sphingolipids. Synthetic sphingolipid synthesis for pharmaceutical uses increased as a result of the expanding demand for lipids, especially in Western Europe.
The market for sphingolipids is primarily driven by rising health consciousness and the resulting rise in demand for wholesome and secure food items. Consumers now place a greater emphasis on healthy eating, value quality over quantity, and choose to purchase fewer but higher-quality, more natural goods.
China has led the regional market with a massive share of about 68.6% and generated revenue of about US$113.6 Million at the end of 2021.
This is spurred on by a rise in sphingolipid demand due to their characteristics, sphingolipids, and their derivatives are highly bioactive substances with anti-cancer, bacteriostatic, and cholesterol-lowering effects. Sphingolipids are in high demand since Chinese consumers use them extensively in their everyday diet.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By product, sphingomyelin has driven the global market with a decent amount of market share of about 29.0% in 2021 and is expected to grow at a CAGR of 5.5%. With anti-cancer, bacteriostatic, and cholesterol-lowering characteristics, sphingolipids and their derivatives, such as sphingomyelin, are extremely bioactive substances. Owing to such properties the market for sphingomyelin is expected to grow exponentially.
By source, synthetic sphingolipids are in demand, and as of 2021, synthetic sphingolipids accounted for US$ 216.5 Million. By disrupting cell signalling, membrane trafficking, and the binding of infectious pathogens, synthetic sphingolipids offer potential as therapeutic candidates for treating a variety of disease conditions. Due to such benefits, the market is anticipated to propel in the future too.
By application, conventional lipid-based drug delivery systems (LBDDS) have driven the market by holding a majority of the market share of about 61.9% and achieved a valuation of US$ 349.1 Million at the end of 2021.
By presenting the pharmaceutical composition in a solubilized condition, as opposed to conventional tablets or powder-filled capsules, LBDDS can improve bioavailability and eliminate dissolving rate-limited absorption. The homogeneity of dosage form content may also be enhanced for medications with high potencies.
By form, semi-solids have led the market by accounting for around US$ 345.5 Million by the end of 2021. This dominance is a result of the advantage that local treatment of a variety of dermatological conditions is made possible by semi-solid dosage forms, such as topical application, with very few systemic side effects.
The probability of negative side effects is decreased when a high drug load is applied to the area where the medication is genuinely required. Topical drugs are easy for the patient to apply, and because of their nourishing qualities, semi-solid dosage forms are beneficial for a range of skin problems.
By end user, pharmaceutical companies have driven the global sphingolipids market by achieving a valuation of US$ 200.2 Million by the end of 2021. Global and diverse pharmaceutical companies have emerged. Pharma manufacturers are dominating the market with increased outsourcing, innovative modalities, and creative patient outreach strategies.
Major manufacturers are concentrating on accelerating the process to boost sales of medications containing sphingolipids. In order to lower the expenses associated with medicine development and production, they are also utilizing technical innovations.
In the upcoming years, the market is anticipated to be driven by this. The main tactics used by manufacturers to boost product sales in different locations include strategic alliances, acquisitions, expansion, new launches, agreements, and research sponsorship.
Similarly, recent developments related to companies manufacturing sphingolipids, have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2012 to 2021 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA). |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Turkey, GCC, South Africa, North Africa and Rest of MEA. |
| Key Market Segments Covered | Product, Source, Form, Application, End User, and Region |
| Key Companies Profiled | Merck KGaA, CordenPharma International, Lipoid GmbH, LARODAN AB, Croda International Plc., Biosynth, Santa Cruz Biotechnology, Inc., Creative Enzymes, CD Bioparticles, Cayman Chemical Company, and Biosolve BV |
| Pricing | Available upon Request |
The global sphingolipids market is worth US$ 564.0 Million at end of 2021.
The sphingolipids market is expected to reach US$ 991.8 Million by end of 2032 at a CAGR of 5.1%.
Molecular and biological developments in sphingolipids providing promising health benefits and increasing sedentary lifestyles among people leading to an increase in the prevalence of cardiovascular diseases and cancer are some of the key factors that drive this market.
The North American region has the highest market share of about 27.6% in 2021 in the global sphingolipids market.
South Asia accounted for about 10.9% of the market share in 2021 in the global sphingolipids market.
The USA, China, Germany, and India are the top five countries, which are expected to drive demand in the sphingolipids market.
Merck KGaA, CordenPharma International, Lipoid GmbH, LARODAN AB, Croda International Plc., Biosynth, Santa Cruz Biotechnology, Inc., Creative Enzymes, CD Bioparticles, Cayman Chemical Company, and Biosolve BV are some of the key players in the sphingolipids industry.
From 2012 to 2021, the market for sphingolipids expanded at the rate of 4.7%.
China accounted for 68.6% of the market share at the end of 2021 in the East Asian market.
Germany displayed a market share of around 32.5% in 2021 in the European sphingolipids market
1. Executive Summary | Sphingolipids Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Product Adoption-Usage Analysis
4.2. Key promotional strategies by manufacturers
4.3. Recent Launches and Approvals
4.4. Regulatory Landscape
4.5. Value chain analysis
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Pharmaceutical Lipids Industry Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Top Companies Historical Growth
5.2.2. Increasing Awareness About lipids’ Health Benefits
5.2.3. Product Pricing
5.2.4. Product Availability
5.2.5. Increasing Research on Modified/Released Formulations
5.2.6. Rising Disposable Income
5.2.7. Growing Applications of Sphingolipids
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Source
6.1.3. By Application
6.1.4. By Form
6.1.5. By End User
6.2. 2021 Market Scenario
7. Global Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis, by Product, 2012 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Product, 2022 to 2032
8.4. Market Attractiveness Analysis, by Product
8.4.1. Ceramide
8.4.2. Sphingomyelin
8.4.3. Glucosylceramide (GlcCer)
8.4.4. Lactosylceramide (LacCer)
8.4.5. Ganglioside GM3
8.4.6. Other
9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Source
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis, by Source, 2012 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Source, 2022 to 2032
9.4. Market Attractiveness Analysis, by Source
9.4.1. Synthetic
9.4.2. Semi-synthetic
9.4.3. Natural
10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis, By Application, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Application, 2022 to 2032
10.3.1. Conventional Lipid-based Drug Delivery Systems (LBDDS)
10.3.2. Self-Emulsifying Drug Delivery Systems (SEDDS)
10.3.3. Self-Microemulsifying Drug Delivery Systems (SMEDDS)
10.3.4. Liposomes
10.3.5. Solid Lipid Nanoparticles
10.3.6. Nanostructured Lipid Carriers
10.3.7. Others
10.4. Market Attractiveness Analysis, by Application
11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Form
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By Form, 2012 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by Form, 20222032
11.3.1. Liquid
11.3.2. Semi-solid
11.3.3. Solid
11.4. Market Attractiveness Analysis, by Form
12. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis, By End User, 2012 to 2021
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast, by End User, 2022 to 2032
12.3.1. Pharmaceutical Companies
12.3.2. Biopharmaceutical Companies
12.3.3. Academics and Research Institutes
12.3.4. Others
12.4. Market Attractiveness Analysis, by End User
13. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis, by Region, 2012 to 2021
13.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis, by Region
14. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021
14.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
14.3.1. By Country
14.3.1.1. United States of America
14.3.1.2. Canada
14.3.2. By Product
14.3.3. By Source
14.3.4. By Application
14.3.5. By Form
14.3.6. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By Source
14.4.4. By Application
14.4.5. By Form
14.4.6. By End User
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country-Level Analysis & Forecast
14.7.1. USA Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast, by Market Taxonomy
14.7.1.2.1. By Product
14.7.1.2.2. By Source
14.7.1.2.3. By Application
14.7.1.2.4. By Form
14.7.1.2.5. By End User
14.7.2. Canada Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast, by Market Taxonomy
14.7.2.2.1. By Product
14.7.2.2.2. By Source
14.7.2.2.3. By Application
14.7.2.2.4. By Form
14.7.2.2.5. By End User
15. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021
15.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
15.3.1. By Country
15.3.1.1. Mexico
15.3.1.2. Brazil
15.3.1.3. Argentina
15.3.1.4. Rest of Latin America
15.3.2. By Product
15.3.3. By Source
15.3.4. By Application
15.3.5. By Form
15.3.6. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Product
15.4.2. By Source
15.4.3. By Application
15.4.4. By Form
15.4.5. By End User
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country-Level Analysis & Forecast
15.7.1. Mexico Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast, by Market Taxonomy
15.7.1.2.1. By Product
15.7.1.2.2. By Source
15.7.1.2.3. By Application
15.7.1.2.4. By Form
15.7.1.2.5. By End User
15.7.2. Brazil Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast, by Market Taxonomy
15.7.2.2.1. By Product
15.7.2.2.2. By Source
15.7.2.2.3. By Application
15.7.2.2.4. By Form
15.7.2.2.5. By End User
15.7.3. Argentina Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast, by Market Taxonomy
15.7.3.2.1. By Product
15.7.3.2.2. By Source
15.7.3.2.3. By Application
15.7.3.2.4. By Form
15.7.3.2.5. By End User
16. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021
16.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
16.3.1. By Country
16.3.1.1. Germany
16.3.1.2. Italy
16.3.1.3. France
16.3.1.4. United Kingdom
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. By Product
16.3.3. By Source
16.3.4. By Application
16.3.5. By Form
16.3.6. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By Source
16.4.4. By Application
16.4.5. By Form
16.4.6. By End User
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country-Level Analysis & Forecast
16.7.1. Germany Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast, by Market Taxonomy
16.7.1.2.1. By Product
16.7.1.2.2. By Source
16.7.1.2.3. By Application
16.7.1.2.4. By Form
16.7.1.2.5. By End User
16.7.2. Italy Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast, by Market Taxonomy
16.7.2.2.1. By Product
16.7.2.2.2. By Source
16.7.2.2.3. By Application
16.7.2.2.4. By Form
16.7.2.2.5. By End User
16.7.3. France Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast, by Market Taxonomy
16.7.3.2.1. By Product
16.7.3.2.2. By Source
16.7.3.2.3. By Application
16.7.3.2.4. By Form
16.7.3.2.5. By End User
16.7.4. UK Market Analysis
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast, by Market Taxonomy
16.7.4.2.1. By Product
16.7.4.2.2. By Source
16.7.4.2.3. By Application
16.7.4.2.4. By Form
16.7.4.2.5. By End User
16.7.5. Spain Market Analysis
16.7.5.1. Introduction
16.7.5.2. Market Analysis and Forecast, by Market Taxonomy
16.7.5.2.1. By Product
16.7.5.2.2. By Source
16.7.5.2.3. By Application
16.7.5.2.4. By Form
16.7.5.2.5. By End User
16.7.6. BENELUX Market Analysis
16.7.6.1. Introduction
16.7.6.2. Market Analysis and Forecast, by Market Taxonomy
16.7.6.2.1. By Product
16.7.6.2.2. By Source
16.7.6.2.3. By Application
16.7.6.2.4. By Form
16.7.6.2.5. By End User
16.7.7. Russia Market Analysis
16.7.7.1. Introduction
16.7.7.2. Market Analysis and Forecast, by Market Taxonomy
16.7.7.2.1. By Product
16.7.7.2.2. By Source
16.7.7.2.3. By Application
16.7.7.2.4. By Form
16.7.7.2.5. By End User
17. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Form (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021
17.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Product
17.3.3. By Source
17.3.4. By Application
17.3.5. By Form
17.3.6. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By Source
17.4.4. By Application
17.4.5. By Form
17.4.6. By End User
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. China Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast, by Market Taxonomy
17.7.1.2.1. By Product
17.7.1.2.2. By Source
17.7.1.2.3. By Application
17.7.1.2.4. By Form
17.7.1.2.5. By End User
17.7.2. Japan Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast, by Market Taxonomy
17.7.2.2.1. By Product
17.7.2.2.2. By Source
17.7.2.2.3. By Application
17.7.2.2.4. By Form
17.7.2.2.5. By End User
17.7.3. South Korea Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast, by Market Taxonomy
17.7.3.2.1. By Product
17.7.3.2.2. By Source
17.7.3.2.3. By Application
17.7.3.2.4. By Form
17.7.3.2.5. By End User
18. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021
18.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Malaysia
18.3.1.4. Thailand
18.3.1.5. Rest of South Asia
18.3.2. By Product
18.3.3. By Source
18.3.4. By Application
18.3.5. By Form
18.3.6. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By Source
18.4.4. By Application
18.4.5. By Form
18.4.6. By End User
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Country-Level Analysis & Forecast
18.7.1. India Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast, by Market Taxonomy
18.7.1.2.1. By Product
18.7.1.2.2. By Source
18.7.1.2.3. By Application
18.7.1.2.4. By Form
18.7.1.2.5. By End User
18.7.2. Indonesia Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast, by Market Taxonomy
18.7.2.2.1. By Product
18.7.2.2.2. By Source
18.7.2.2.3. By Application
18.7.2.2.4. By Form
18.7.2.2.5. By End User
18.7.3. Malaysia Market Analysis
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast, by Market Taxonomy
18.7.3.2.1. By Product
18.7.3.2.2. By Source
18.7.3.2.3. By Application
18.7.3.2.4. By Form
18.7.3.2.5. By End User
18.7.4. Thailand Market Analysis
18.7.4.1. Introduction
18.7.4.2. Market Analysis and Forecast, by Market Taxonomy
18.7.4.2.1. By Product
18.7.4.2.2. By Source
18.7.4.2.3. By Application
18.7.4.2.4. By Form
18.7.4.2.5. By End User
19. Oceania 2012 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021
19.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Product
19.3.3. By Source
19.3.4. By Application
19.3.5. By Form
19.3.6. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By Source
19.4.4. By Application
19.4.5. By Form
19.4.6. By End User
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
19.7. Country-Level Analysis & Forecast
19.7.1. Australia Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast, by Market Taxonomy
19.7.1.2.1. By Product
19.7.1.2.2. By Source
19.7.1.2.3. By Application
19.7.1.2.4. By Form
19.7.1.2.5. By End User
19.7.2. New Zealand Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast, by Market Taxonomy
19.7.2.2.1. By Product
19.7.2.2.2. By Source
19.7.2.2.3. By Application
19.7.2.2.4. By Form
19.7.2.2.5. By End User
20. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032
20.1. Introduction
20.2. Historical Market Size (US$ Million) Analysis Trend Analysis, by Market Taxonomy, 2012 to 2021
20.3. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Turkey
20.3.1.3. South Africa
20.3.1.4. North Africa
20.3.1.5. Rest of Middle East and Africa
20.3.2. By Product
20.3.3. By Source
20.3.4. By Application
20.3.5. By Form
20.3.6. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Product
20.4.2. By Source
20.4.3. By Application
20.4.4. By Form
20.4.5. By End User
20.5. Market Trends
20.6. Drivers and Restraints - Impact Analysis
20.7. Country-Level Analysis & Forecast
20.7.1. GCC Countries Market Analysis
20.7.1.1. Introduction
20.7.1.2. Market Analysis and Forecast, by Market Taxonomy
20.7.1.2.1. By Product
20.7.1.2.2. By Source
20.7.1.2.3. By Application
20.7.1.2.4. By Form
20.7.1.2.5. By End User
20.7.2. Turkey Market Analysis
20.7.2.1. Introduction
20.7.2.2. Market Analysis and Forecast, by Market Taxonomy
20.7.2.2.1. By Product
20.7.2.2.2. By Source
20.7.2.2.3. By Application
20.7.2.2.4. By Form
20.7.2.2.5. By End User
20.7.3. South Africa Market Analysis
20.7.3.1. Introduction
20.7.3.2. Market Analysis and Forecast, by Market Taxonomy
20.7.3.2.1. By Product
20.7.3.2.2. By Source
20.7.3.2.3. By Application
20.7.3.2.4. By Form
20.7.3.2.5. By End User
20.7.4. North Africa Safety Needles Market
20.7.4.1. Introduction
20.7.4.2. Market Analysis and Forecast, by Market Taxonomy
20.7.4.2.1. By Product
20.7.4.2.2. By Source
20.7.4.2.3. By Application
20.7.4.2.4. By Form
20.7.4.2.5. By End User
21. Market Structure Analysis
21.1. Market Analysis, by Tier of Companies
21.2. Market Share Analysis of Top Players
21.3. Market Presence Analysis
22. Competition Analysis
22.1. Competition Dashboard
22.2. Competition Benchmarking
22.3. Competition Deep Dive
22.3.1. Merck KGaA
22.3.1.1. Overview
22.3.1.2. Product Portfolio
22.3.1.3. Profitability by Market Segments (Product/Channel/Region)
22.3.1.4. Sales Footprint
22.3.1.5. Key Financials
22.3.1.6. SWOT Analysis
22.3.1.7. Strategy Overview
22.3.2. CordenPharma International
22.3.2.1. Overview
22.3.2.2. Product Portfolio
22.3.2.3. Profitability by Market Segments (Product/Channel/Region)
22.3.2.4. Sales Footprint
22.3.2.5. Key Financials
22.3.2.6. SWOT Analysis
22.3.2.7. Strategy Overview
22.3.3. Lipoid GmbH
22.3.3.1. Overview
22.3.3.2. Product Portfolio
22.3.3.3. Profitability by Market Segments (Product/Channel/Region)
22.3.3.4. Sales Footprint
22.3.3.5. Key Financials
22.3.3.6. SWOT Analysis
22.3.3.7. Strategy Overview
22.3.4. LARODAN AB
22.3.4.1. Overview
22.3.4.2. Product Portfolio
22.3.4.3. Profitability by Market Segments (Product/Channel/Region)
22.3.4.4. Sales Footprint
22.3.4.5. Key Financials
22.3.4.6. SWOT Analysis
22.3.4.7. Strategy Overview
22.3.5. Croda International Plc.
22.3.5.1. Overview
22.3.5.2. Product Portfolio
22.3.5.3. Profitability by Market Segments (Product/Channel/Region)
22.3.5.4. Sales Footprint
22.3.5.5. Key Financials
22.3.5.6. SWOT Analysis
22.3.5.7. Strategy Overview
22.3.6. Biosynth
22.3.6.1. Overview
22.3.6.2. Product Portfolio
22.3.6.3. Profitability by Market Segments (Product/Channel/Region)
22.3.6.4. Sales Footprint
22.3.6.5. Key Financials
22.3.6.6. SWOT Analysis
22.3.6.7. Strategy Overview
22.3.7. Santa Cruz Biotechnology, Inc.
22.3.7.1. Overview
22.3.7.2. Product Portfolio
22.3.7.3. Profitability by Market Segments (Product/Channel/Region)
22.3.7.4. Sales Footprint
22.3.7.5. Key Financials
22.3.7.6. SWOT Analysis
22.3.7.7. Strategy Overview
22.3.8. Creative Enzymes
22.3.8.1. Overview
22.3.8.2. Product Portfolio
22.3.8.3. Profitability by Market Segments (Product/Channel/Region)
22.3.8.4. Sales Footprint
22.3.8.5. Key Financials
22.3.8.6. SWOT Analysis
22.3.8.7. Strategy Overview
22.3.9. CD Bioparticles
22.3.9.1. Overview
22.3.9.2. Product Portfolio
22.3.9.3. Profitability by Market Segments (Product/Channel/Region)
22.3.9.4. Sales Footprint
22.3.9.5. Key Financials
22.3.9.6. SWOT Analysis
22.3.9.7. Strategy Overview
22.3.10. Cayman Chemical Company
22.3.10.1. Overview
22.3.10.2. Product Portfolio
22.3.10.3. Profitability by Market Segments (Product/Channel/Region)
22.3.10.4. Sales Footprint
22.3.10.5. Key Financials
22.3.10.6. SWOT Analysis
22.3.10.7. Strategy Overview
22.3.11. Biosolve BV
22.3.11.1. Overview
22.3.11.2. Product Portfolio
22.3.11.3. Profitability by Market Segments (Product/Channel/Region)
22.3.11.4. Sales Footprint
22.3.11.5. Key Financials
22.3.11.6. SWOT Analysis
22.3.11.7. Strategy Overview
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports
Sphingolipids Market
